Lice Treatment Market Size & Share 2026-2035

Lice Treatment Market Size

The global lice treatment market was valued at USD 1.16 billion in 2025. The market is expected to grow from USD 1.23 billion in 2026 to USD 2.3 billion in 2035, at a CAGR of 7.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is driven primarily by the persistent prevalence of lice infestations worldwide and the growing demand for effective treatment solutions. Head lice infestations remain highly common among school-aged children and are easily transmitted through close personal contact in schools, daycare centers, camps, and households. The recurring nature of infestations and the need for prompt treatment continue to support the adoption of both over-the-counter (OTC) and prescription lice treatment products, thereby contributing to market expansion.

Lice treatment encompasses a range of therapeutic approaches designed to eliminate lice infestations and prevent reinfestation. These treatments target both adult lice and their eggs (nits) through medicated shampoos, lotions, creams, sprays, oral medications, and specialized combing devices. Modern treatment options increasingly incorporate novel active ingredients, resistance-management strategies, and non-chemical alternatives to address growing concerns regarding treatment-resistant lice populations and product safety.

The market is characterized by the presence of several established pharmaceutical and consumer healthcare companies, including Perrigo Company, Prestige Consumer Healthcare, Johnson & Johnson, Alliance Pharma, Arbor Pharmaceuticals, TecLabs, and STADA Arzneimittel. These market participants continue to strengthen their positions through product innovation, expansion of OTC and prescription portfolios, development of resistance-effective formulations, and introduction of non-toxic and device-based treatment solutions. Strategic collaborations, wider retail and e-commerce distribution networks, and geographic expansion initiatives further support market growth and competitive differentiation.

The lice treatment market witnessed steady growth during this period was supported by rising awareness regarding lice management, increased accessibility of treatment products, and the growing utilization of advanced therapies such as ivermectin- and spinosad-based treatments. Additionally, consumer preference for safer, pesticide-free, and natural treatment alternatives, coupled with ongoing efforts to address insecticide resistance, contributed significantly to market development across North America, Europe, and emerging Asia-Pacific countries.
 

Lice Treatment Market Trends

• The lice treatment industry is experiencing strong growth due to the widespread availability of treatment products across pharmacies, supermarkets, drug stores, and e-commerce platforms. The extensive distribution network enables consumers to access treatment solutions conveniently and promptly, supporting higher product adoption rates.
• The easy accessibility of over the counter (OTC) drugs allows individuals to begin treatment immediately without requiring a prescription. Early intervention helps contain infestations, reduces transmission risks, and improves treatment outcomes, thereby contributing to market expansion.
• A growing consumer preference for non-chemical and natural treatment options is emerging as a prominent market trend. Increasing demand for plant-based, silicone-based, and pesticide-free formulations reflects heightened awareness regarding safety, particularly for children and individuals requiring repeated treatments.
• The adoption of device-based and mechanical lice removal technologies is also gaining momentum. Solutions such as electronic lice combs, suction devices, and heated-air treatment systems are increasingly being utilized as effective, resistance-free alternatives to conventional chemical therapies.
• Furthermore, concerns regarding treatment-resistant lice populations are encouraging manufacturers to invest in innovative formulations with novel mechanisms of action. The development of resistance-aware products is improving treatment efficacy and strengthening the market's innovation pipeline.
• The continued expansion of digital commerce platforms and direct-to-consumer sales channels is enhancing product accessibility and purchasing convenience. Online distribution also provides a discreet purchasing experience, which is increasingly valued by consumers seeking privacy.
• Additionally, increasing awareness campaigns, school-based screening programs, and community health initiatives are promoting early diagnosis and timely treatment. These efforts are supporting sustained demand for both preventive and therapeutic lice management products across key markets

Lice Treatment Market Analysis

Based on the product type, the lice treatment market is segmented into OTC products, and prescription medications. The OTC products segment dominated in 2025 and is anticipated to grow at a CAGR of 7.4% over the forecast years.

• The OTC products segment is further categorized into permethrin, pyrethrin, and other OTC products.
• The segment’s dominance is primarily attributed to the widespread availability of OTC treatments, enabling consumers to initiate therapy immediately upon detecting a lice infestation without requiring a physician's prescription. This accessibility promotes timely treatment and helps limit transmission.
• Growing consumer preference for safer and environmentally friendly treatment options is further supporting segment growth, with increasing demand for non-toxic, pesticide-free, and eco-conscious formulations.
• Strong brand recognition, established consumer confidence, and high repeat purchase rates associated with recurrent infestations, particularly among school-aged children, continue to reinforce the segment’s market leadership.
• Additionally, extensive promotional activities, awareness initiatives, and educational campaigns conducted by manufacturers and healthcare organizations are encouraging early self-treatment and expanding the adoption of OTC lice management products.

Based on the type, the lice treatment market is segmented into branded and generic. The branded segment dominated the market and is expected to reach USD 1.3 billion by end of 2035.

• The branded segment maintains its leading position owing to strong consumer trust, extensive product visibility, and established market presence of leading consumer healthcare companies.
• Branded products are often perceived as offering superior reliability, quality assurance, and proven clinical efficacy, making them a preferred choice among parents and caregivers seeking effective treatment solutions.
• Furthermore, these products benefit from broad retail availability, consistent formulation quality, and recurring demand resulting from reinfestation concerns. Widely recognized brands such as RID and Nix continue to maintain strong market penetration through their longstanding presence and proven effectiveness.
• Conversely, the generic segment is expected to witness the fastest growth over the forecast period, driven by increasing cost-consciousness among consumers and growing acceptance of affordable therapeutic alternatives.

Based on route of administration, the lice treatment market is classified into oral and topical. The topical segment dominated the market in 2025 with USD 1 billion.

• The segment dominates due to its localized mechanism of action, direct application to the affected area, and long-established clinical acceptance in lice management.
• Topical formulations, including shampoos, topical antibiotics, creams, sprays, mousses, and other topical treatments, are widely preferred because they effectively target lice while minimizing systemic exposure.
• Ongoing product development efforts aimed at enhancing ease of application, treatment effectiveness, and duration of action continue to strengthen the segment’s growth prospects.
• The oral segment, while representing a comparatively smaller market share, plays an important role in managing severe infestations and treatment-resistant cases. Prescription oral therapies provide systemic action and are typically utilized when topical interventions prove ineffective.

Based on condition, the lice treatment market is classified into pediculosis capitis, pediculosis corporis, and pediculosis pubis. The pediculosis capitis segment accounted for market share of 78.8% in 2025.

• Pediculosis capitis represents the largest segment owing to its high prevalence, particularly among children and school-aged populations where close interpersonal contact facilitates rapid transmission.
• The frequent occurrence of head lice infestations generates consistent demand for treatment and preventive solutions, making pediculosis capitis the primary revenue-generating condition segment.
• Increasing awareness regarding early diagnosis and management has further encouraged treatment uptake and supported market growth.
• In addition, integrated management approaches that combine topical therapies, environmental hygiene measures, nit removal strategies, and educational programs are gaining wider acceptance, improving treatment outcomes and reducing recurrence rates.

Based on dosage form, the lice treatment market is classified into tablets, shampoos, lotions, cream, and other dosage forms. The shampoos segment is expected to reach USD 881.8 million by end of 2035.

• Shampoos remain the most widely utilized dosage form due to their convenience, ease of application, and familiarity among consumers, particularly parents treating children affected by lice infestations.
• These formulations are designed for simple application and rinsing, reducing treatment complexity while enhancing user compliance.
• Broad product availability across retail pharmacies, supermarkets, and online platforms has further strengthened the segment’s adoption worldwide.
• Strong brand loyalty and repeated treatment requirements associated with reinfestation continue to support stable demand and substantial revenue generation for shampoo-based products.
• Meanwhile, the lotions segment is anticipated to register the fastest growth during the forecast period. Superior scalp coverage, prolonged contact time, and enhanced treatment efficacy are key factors driving the increasing adoption of lotion formulations.

By distribution channel, the lice treatment market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. The retail pharmacies segment accounted for market share of 56.4% in 2025.

• Retail pharmacies dominate the distribution landscape due to their extensive geographic presence and easy accessibility to consumers seeking immediate treatment solutions.
• These outlets offer a comprehensive range of OTC lice treatment products, including medicated shampoos, lotions, sprays, combs, and complementary treatment accessories, enabling consumers to compare and select products based on their specific needs.
• Retail pharmacies are often the preferred point of purchase for parents and caregivers seeking prompt and convenient treatment options, particularly following the identification of lice infestations in schools or households.
• The availability of diverse product offerings, pharmacist guidance, and growing consumer confidence in self-care solutions continues to drive strong sales through retail pharmacy channels, supporting overall market growth.

North America Lice Treatment Market

The North America market dominated the lice treatment industry with a market share of 39.1% in 2025.

• The region’s leadership is supported by a high prevalence of head lice infestations among school-aged children, strong healthcare awareness, and widespread availability of treatment products through pharmacies, supermarkets, and online channels.
• Manufacturers continue to expand their product portfolios with OTC medications, prescription therapies, natural formulations, and device-based solutions, providing consumers with a broad range of treatment options.
• The growing focus on early diagnosis, self-care management, and resistance-effective formulations further supports market growth across the region.

The U.S. lice treatment market size reached USD 412.7 million in 2025, growing from USD 392.1 million in 2024.

• The U.S. market benefits from extensive OTC product availability, strong consumer awareness, and well-established retail pharmacy networks, enabling rapid treatment initiation and high product accessibility.
• School-based screening initiatives, parental education programs, and increasing awareness regarding infestation prevention contribute to consistent demand for lice treatment products.
• The country is witnessing growing adoption of advanced treatment options, including silicone-based products, prescription therapies, and device-assisted solutions designed to address treatment-resistant infestations.
• Furthermore, the presence of leading consumer healthcare companies and continuous product innovation support market expansion and premium product adoption.

Europe Lice Treatment Market

Europe market accounted for USD 317.9 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Market growth is supported by robust healthcare systems, widespread access to pharmacy-dispensed treatments, and strong public health awareness regarding lice prevention and management.
• School screening programs and routine pediatric healthcare visits contribute to early detection and timely treatment across several European countries.
• Increasing demand for natural, low-toxicity, and dermatologically tested products is driving product innovation and supporting market expansion throughout the region.
• Rising consumer preference for safer treatment alternatives and growing adoption of non-chemical solutions are further contributing to market growth.

Germany lice treatment market dominates the Europe market, with strong growth potential.

• Strong emphasis on preventive healthcare and early intervention encourages timely treatment adoption, particularly among families with school-aged children.
• High consumer confidence in pharmacist-recommended products and extensive availability of both branded and private-label treatments support market growth.
• Germany's large urban population, high mobility rates, and strong healthcare infrastructure contribute to sustained demand for lice management products.
• Additionally, increasing consumer interest in natural and clinically validated treatment options continues to drive product uptake.

Asia Pacific Lice Treatment Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 7.8% during the analysis timeframe.

• Growth is driven by rising hygiene awareness, increasing healthcare expenditure, expanding access to OTC healthcare products, and growing awareness of lice-related conditions.
• Rapid urbanization, increasing school enrollment rates, and improving healthcare infrastructure are contributing to greater demand for treatment and prevention solutions.
• The expansion of retail pharmacy networks and e-commerce platforms across major economies is significantly improving product accessibility and market penetration.
• Growing middle-class populations and rising consumer spending on personal healthcare products further support regional market growth.

China lice treatment market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• The country's large population base, dense urban environments, and high concentration of school-going children create favorable conditions for the transmission of lice infestations.
• Increasing adoption of self-medication practices and wider availability of affordable OTC products are supporting treatment uptake.
• Domestic manufacturers are expanding production capabilities and introducing cost-effective treatment solutions, improving product accessibility across urban and rural areas.
• Government efforts to promote public hygiene awareness and preventive healthcare practices continue to strengthen demand for lice treatment products.

Latin American Lice Treatment Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• The high incidence of head lice infestations among children remains a key factor driving demand for treatment products across the country.
• Expansion of organized retail pharmacy chains and improved healthcare accessibility are increasing product availability in both urban and semi-urban regions.
• Growing awareness regarding personal hygiene and infestation management is encouraging earlier treatment adoption among consumers.
• The increasing availability of affordable generic products and locally manufactured formulations is further supporting market penetration and expanding access to treatment options.

Middle East and Africa Lice Treatment Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2025.

• Market growth is supported by rising healthcare expenditure, increasing awareness of personal hygiene practices, and ongoing investments in healthcare infrastructure.
• School health programs and public awareness campaigns are promoting early identification and treatment of lice infestations, supporting product demand.
• Expanding pharmacy networks and improved access to OTC healthcare products are enhancing treatment accessibility across the country.
• Additionally, rapid urbanization, growing expatriate populations, and increasing international travel are contributing to greater awareness and demand for effective lice management solutions.

Lice Treatment Market Share

The lice treatment industry is characterized by a fragmented yet competitive landscape, with a core group of multinational consumer healthcare and pharmaceutical companies accounting for a meaningful share of overall revenues. Reckitt Benckiser, Perrigo, Sanofi, Prestige Consumer Healthcare, and Teva Pharmaceutical collectively contribute to approximately 40% of the global market, supported by their strong brand portfolios, established OTC and prescription offerings, and extensive retail and pharmacy‑based distribution networks. These players maintain leadership across key treatment categories, including shampoos, lotions, and prescription pediculicides, addressing both first‑line and treatment‑resistant infestations.

Competition in the market is primarily driven by brand strength, wide OTC availability, pricing strategies, and formulation innovation, particularly in response to growing concerns around resistance, safety, and pediatric use. Leading companies continue to reinforce their positions by expanding product lines, strengthening private‑label portfolios, and optimizing supply chains to improve accessibility across developed and emerging markets. Their dominance is further supported by strong relationships with pharmacies, mass retailers, and online platforms, enabling consistent consumer reach.

Strategic initiatives such as product reformulations, marketing partnerships, and targeted portfolio expansions continue to shape competitive dynamics. Companies are increasingly focusing on resistance‑effective solutions, non‑toxic and silicone‑based formulations, and dermatologically tested products to maintain competitiveness. While the market remains fragmented with numerous regional and niche players, the leading companies are well positioned to sustain their collective share through continuous innovation, brand loyalty, and broad geographic presence, supported by recurring demand driven by reinfestation patterns and preventive treatment adoption.

Lice Treatment Market Companies

Prominent players operating in the lice treatment industry include:

• Alliance Pharma
• Azurity Pharmaceuticals
• Cooper Laboratories
• ICB PHARMA
• Lice Clinics of America
• Oystershell Consumer Health
• Perrigo
• Prestige Consumer Healthcare
• Reckitt Benckiser
• Sanofi
•  STADA Arzneimittel
• Sun Pharmaceutical
• TecLabs
• Teva Pharmaceutical

• Reckitt Benckiser

Reckitt Benckiser holds a leading position in the lice treatment market, supported by its flagship RID brand and a strong consumer health portfolio focused on OTC solutions. The company’s dominance is reinforced by broad geographic reach, strong brand equity, and extensive penetration across pharmacies, supermarkets, and online retail channels. Reckitt’s consistent investment in product innovation, including resistance‑effective and user‑friendly formulations, strengthens its market leadership.

• Perrigo

Perrigo maintains a strong competitive standing in the lice treatment industry, driven by its extensive portfolio of branded and private‑label OTC lice treatment products. The company benefits from deep integration with retail pharmacy networks and mass merchants, enabling wide consumer access and cost‑competitive offerings. Perrigo’s leadership is reinforced by its focus on affordable, high‑quality alternatives that cater to recurring treatment needs and price‑sensitive consumers.

Lice Treatment Industry News

• In January 2026, Pelthos Therapeutics acquired Xeglyze (abametapir), an FDA‑approved topical prescription treatment for head lice, from Hatchtech, gaining worldwide commercialization rights with no future royalty obligations. The acquisition expanded Pelthos commercial portfolio with a differentiated prescription asset addressing unmet needs in lice treatment.
• In February 2024, Quest Products acquired Tec Laboratories, adding the Tecnu and Licefreee non‑toxic head lice treatment brands to itself‑care product portfolio. The acquisition strengthened Quest’s presence in the lice treatment and first‑aid self‑care segments by broadening its branded offerings.
• In October 2022, Alliance Pharmaceuticals, in partnership with South Florida Family Health and Research Centers, initiated a clinical trial to assess the safety and effectiveness of Vamousse Spray 'n' Go compared to a 1% Permethrin control shampoo for treating head lice. This clinical trial aim to provide valuable insights into the performance of Vamousse Spray 'n' Go in combating head lice infestations, offering a potential alternative or improvement over existing treatment options.

The lice treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• OTC products
  • Permethrin
  • Pyrethrin
  • Other OTC products
• Prescription medications
  • Ivermectin
  • Spinosad
  • Malathion
  • Other prescription medications

Market, By Type

• Branded
• Generic

Market, By Route of Administration

• Oral
• Topical

Market, By Condition

• Pediculosis capitis
• Pediculosis corporis
• Pediculosis pubis

Market, By Dosage Form

• Tablets
• Shampoos
• Lotions
• Cream
• Other dosage forms

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE